Cargando…

Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program

SIMPLE SUMMARY: Patients receiving oral anticancer agents (OAAs) have a substantial symptom burden. Given the trend toward patient-centered care, the use of patient-reported outcomes (PROs) seems appropriate to secure medication management, and to improve clinical decision-making. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Collomb, Bastien, Dubromel, Amélie, Caffin, Anne Gaëlle, Herledan, Chloé, Larbre, Virginie, Baudouin, Amandine, Cerutti, Ariane, Couturier, Laurence, Maire, Magali, Karlin, Lionel, Maucort-Boulch, Delphine, Huot, Laure, Dalle, Stéphane, Bachy, Emmanuel, Ghesquieres, Hervé, Salles, Gilles, Couraud, Sébastien, You, Benoit, Freyer, Gilles, Trillet-Lenoir, Véronique, Ranchon, Florence, Rioufol, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833408/
https://www.ncbi.nlm.nih.gov/pubmed/35158928
http://dx.doi.org/10.3390/cancers14030660
_version_ 1784648934545686528
author Collomb, Bastien
Dubromel, Amélie
Caffin, Anne Gaëlle
Herledan, Chloé
Larbre, Virginie
Baudouin, Amandine
Cerutti, Ariane
Couturier, Laurence
Maire, Magali
Karlin, Lionel
Maucort-Boulch, Delphine
Huot, Laure
Dalle, Stéphane
Bachy, Emmanuel
Ghesquieres, Hervé
Salles, Gilles
Couraud, Sébastien
You, Benoit
Freyer, Gilles
Trillet-Lenoir, Véronique
Ranchon, Florence
Rioufol, Catherine
author_facet Collomb, Bastien
Dubromel, Amélie
Caffin, Anne Gaëlle
Herledan, Chloé
Larbre, Virginie
Baudouin, Amandine
Cerutti, Ariane
Couturier, Laurence
Maire, Magali
Karlin, Lionel
Maucort-Boulch, Delphine
Huot, Laure
Dalle, Stéphane
Bachy, Emmanuel
Ghesquieres, Hervé
Salles, Gilles
Couraud, Sébastien
You, Benoit
Freyer, Gilles
Trillet-Lenoir, Véronique
Ranchon, Florence
Rioufol, Catherine
author_sort Collomb, Bastien
collection PubMed
description SIMPLE SUMMARY: Patients receiving oral anticancer agents (OAAs) have a substantial symptom burden. Given the trend toward patient-centered care, the use of patient-reported outcomes (PROs) seems appropriate to secure medication management, and to improve clinical decision-making. The aim of this study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by OAAs using PROs. In total, 407 questionnaires were completed by 63 patients, in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms most commonly experienced were fatigue, various psychological disorders and general pain. This initiative is the first step in the implementation of symptom assessment by PROs in patients treated by OAAs. The results highlight the need for close coordination between community and hospital health professionals, and the integration of patient self-reporting systems in oncologic clinical practice. ABSTRACT: Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Methods Between September 2018 and May 2019, outpatients starting OAAs were included in a 12-week follow-up to assess 15 symptoms listed in the National Cancer Institute PRO Common Terminology Criteria for Adverse Events, using a 5-point scale of severity or frequency. Patients were requested to alert a referral nurse or pharmacist when they self-assessed high-level (level 3 or 4) symptoms. Results 407 questionnaires were completed by 63 patients in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms that were most commonly experienced were fatigue (>9 in 10 patients; 13.2% of symptoms declared), various psychological disorders (>9 in 10 patients; 28.6% of symptoms declared) and general pain (>8 in 10 patients; 9.4% of symptoms declared). Conclusion PROs are appropriate to detect potential adverse events in cancer outpatients treated by OAAs. This study is the first step for integrating the patient’s perspective in a digital e-health device in routine oncology care.
format Online
Article
Text
id pubmed-8833408
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88334082022-02-12 Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program Collomb, Bastien Dubromel, Amélie Caffin, Anne Gaëlle Herledan, Chloé Larbre, Virginie Baudouin, Amandine Cerutti, Ariane Couturier, Laurence Maire, Magali Karlin, Lionel Maucort-Boulch, Delphine Huot, Laure Dalle, Stéphane Bachy, Emmanuel Ghesquieres, Hervé Salles, Gilles Couraud, Sébastien You, Benoit Freyer, Gilles Trillet-Lenoir, Véronique Ranchon, Florence Rioufol, Catherine Cancers (Basel) Article SIMPLE SUMMARY: Patients receiving oral anticancer agents (OAAs) have a substantial symptom burden. Given the trend toward patient-centered care, the use of patient-reported outcomes (PROs) seems appropriate to secure medication management, and to improve clinical decision-making. The aim of this study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by OAAs using PROs. In total, 407 questionnaires were completed by 63 patients, in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms most commonly experienced were fatigue, various psychological disorders and general pain. This initiative is the first step in the implementation of symptom assessment by PROs in patients treated by OAAs. The results highlight the need for close coordination between community and hospital health professionals, and the integration of patient self-reporting systems in oncologic clinical practice. ABSTRACT: Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Methods Between September 2018 and May 2019, outpatients starting OAAs were included in a 12-week follow-up to assess 15 symptoms listed in the National Cancer Institute PRO Common Terminology Criteria for Adverse Events, using a 5-point scale of severity or frequency. Patients were requested to alert a referral nurse or pharmacist when they self-assessed high-level (level 3 or 4) symptoms. Results 407 questionnaires were completed by 63 patients in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms that were most commonly experienced were fatigue (>9 in 10 patients; 13.2% of symptoms declared), various psychological disorders (>9 in 10 patients; 28.6% of symptoms declared) and general pain (>8 in 10 patients; 9.4% of symptoms declared). Conclusion PROs are appropriate to detect potential adverse events in cancer outpatients treated by OAAs. This study is the first step for integrating the patient’s perspective in a digital e-health device in routine oncology care. MDPI 2022-01-28 /pmc/articles/PMC8833408/ /pubmed/35158928 http://dx.doi.org/10.3390/cancers14030660 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Collomb, Bastien
Dubromel, Amélie
Caffin, Anne Gaëlle
Herledan, Chloé
Larbre, Virginie
Baudouin, Amandine
Cerutti, Ariane
Couturier, Laurence
Maire, Magali
Karlin, Lionel
Maucort-Boulch, Delphine
Huot, Laure
Dalle, Stéphane
Bachy, Emmanuel
Ghesquieres, Hervé
Salles, Gilles
Couraud, Sébastien
You, Benoit
Freyer, Gilles
Trillet-Lenoir, Véronique
Ranchon, Florence
Rioufol, Catherine
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title_full Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title_fullStr Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title_full_unstemmed Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title_short Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
title_sort assessment of patient reported outcomes (pros) in outpatients taking oral anticancer drugs included in the real-life oncoral program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833408/
https://www.ncbi.nlm.nih.gov/pubmed/35158928
http://dx.doi.org/10.3390/cancers14030660
work_keys_str_mv AT collombbastien assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT dubromelamelie assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT caffinannegaelle assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT herledanchloe assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT larbrevirginie assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT baudouinamandine assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT ceruttiariane assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT couturierlaurence assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT mairemagali assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT karlinlionel assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT maucortboulchdelphine assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT huotlaure assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT dallestephane assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT bachyemmanuel assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT ghesquieresherve assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT sallesgilles assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT couraudsebastien assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT youbenoit assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT freyergilles assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT trilletlenoirveronique assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT ranchonflorence assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram
AT rioufolcatherine assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram